跨国药企在华战略的舍与得：“老药”逐步退场，“本土”加速成长

Group 1: Event Overview - The 8th China International Import Expo (CIIE) is held in Shanghai from November 5 to 10, featuring 290 Fortune 500 and industry-leading companies, marking record highs in exhibition area and total number of exhibitors, showcasing the vitality of China's large-scale market [1] - The medical devices and healthcare exhibition area serves as a key window to observe global medical trends, with multinational pharmaceutical companies presenting innovative "black technology products," including AI-enabled drug development and next-generation precision radiotherapy platforms [1] Group 2: Industry Trends - Compared to previous expos, this year's event highlights two intertwined industry trends: multinational pharmaceutical companies are withdrawing from long-listed, declining profit margin "old original research drugs" to focus resources on innovative drug development and cutting-edge technology collaboration [1] - Geopolitical factors and supply chain risks are prompting a consensus on localizing operations in China, with more multinational companies establishing R&D centers and production bases in China to create global supply chain hubs [1] Group 3: R&D and Innovation - The National Medical Products Administration announced the cancellation of 80 drug registration certificates, including products from foreign and joint-venture companies, indicating a trend of "active contraction" among foreign pharmaceutical companies in response to normalized centralized procurement and competitive restructuring [2] - Multinational pharmaceutical companies are increasing R&D investments in innovative drugs for the Chinese market, with companies like Boehringer Ingelheim planning to invest over 5 billion yuan in R&D in China over the next five years [2] - Domestic biotech companies are shifting from "technology introduction" to "technology output," with a growing focus on innovative therapies, including ADCs and PD-1, and China becoming a leading country in CAR-T technology projects [3] Group 4: Localization and Supply Chain - Localization has become a key term for multinational pharmaceutical companies, driven by the need to mitigate geopolitical risks and recognize China's manufacturing and innovation capabilities [5] - A report indicates that over 60% of companies are enhancing supply security through increased regional/local procurement or advancing local production, particularly in markets emphasizing self-sufficiency [6] - Medical device company Varian announced plans for full localization of its product line by 2025, with 60% of its products exported to over 120 countries and regions [6][7] - Cytiva has achieved 25% of its revenue from local manufacturing in China, with plans to increase this to 50% in the next 3 to 5 years [8]